Referral patterns between high- and low-volume centers and associations with uterine cancer treatment and survival: a population-based study of Medicare, Medicaid, and privately insured women

American Journal of Obstetrics and Gynecology

Volumn 215, Issue 4, 2016, Pages 447.e1-447.e13

  Doll, Kemi M ^a,b,c   Meng, Ke ^c   Gehrig, Paola A ^a,c   Brewster, Wendy R ^a,c   Meyer, Anne Marie ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

high volume; outcomes; treatment patterns; uterine cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; CANCER CHEMOTHERAPY; CANCER REGISTRY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; COMORBIDITY; CONFERENCE PAPER; CONTROLLED STUDY; ENDOMETRIUM BIOPSY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HISTOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MEDICAID; MEDICARE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NORTH CAROLINA; PATIENT REFERRAL; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; RETROSPECTIVE STUDY; UTERUS CANCER; ADJUVANT CHEMOTHERAPY; ADMINISTRATIVE CLAIMS (HEALTH CARE); BIOPSY; EPIDEMIOLOGY; HEALTH INSURANCE; HIGH VOLUME HOSPITAL; HYSTERECTOMY; LOW VOLUME HOSPITAL; MORTALITY; PATHOLOGY; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; UNITED STATES; UTERINE NEOPLASMS; YOUNG ADULT;

ADMINISTRATIVE CLAIMS, HEALTHCARE; ADULT; AGED; BIOPSY; CHEMOTHERAPY, ADJUVANT; FEMALE; HOSPITALS, HIGH-VOLUME; HOSPITALS, LOW-VOLUME; HUMANS; HYSTERECTOMY; INSURANCE, HEALTH; LYMPH NODE EXCISION; MEDICAID; MEDICARE; MIDDLE AGED; NORTH CAROLINA; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; SURVIVAL RATE; UNITED STATES; UTERINE NEOPLASMS; YOUNG ADULT;

EID: 84973137772     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2016.04.020     Document Type: Conference Paper

References (32)

1. 1 Wright, J.D., Lewin, S.N., Deutsch, I., et al. Effect of surgical volume on morbidity and mortality of abdominal hysterectomy for endometrial cancer. Obstet Gynecol 117 (2011), 1051–1059.
2. 2 Wright, J.D., Hershman, D.L., Burke, W.M., et al. Influence of surgical volume on outcome for laparoscopic hysterectomy for endometrial cancer. Ann Surg Oncol 19 (2012), 948–958.
3. 3 Chan, J.K., Sherman, A.E., Kapp, D.S., et al. Influence of gynecologic oncologists on the survival of patients with endometrial cancer. J Clin Oncol 29 (2011), 832–838.
4. 4 Wright, J.D., Neugut, A.I., Lewin, S.N., et al. Trends in hospital volume and patterns of referral for women with gynecologic cancers. Obstet Gynecol 121 (2013), 1217–1225.
5. 5 Gunderson, C.C., Tergas, A.I., Fleury, A.C., et al. Primary uterine cancer in Maryland: impact of distance on access to surgical care at high-volume hospitals. Int J Gynecol Cancer 23 (2013), 1244–1251.
6. 6 Benjamin, I., Dalton, H., Qiu, Y., et al. Endometrial cancer surgery in Arizona: a statewide analysis of access to care. Gynecol Oncol 121 (2011), 83–86.
7. 7 Burke, W.M., Orr, J., Leitao, M., et al. Endometrial cancer: a review and current management strategies: part II. Gynecol Oncol 134 (2014), 393–402.
8. 8 Burke, W.M., Orr, J., Leitao, M., et al. Endometrial cancer: a review and current management strategies: part I. Gynecol Oncol 134 (2014), 385–392.
9. 9 Endometrial cancer. Practice bulletin no. 149. Obstet Gynecol 125 (2015), 1006–1026.
10. 10 Uterine neoplams, NCCN clinical practice guidelines in oncology, National Comprehensive Cancer Network, 2016. Available at: www.nccn.org. Accessed June 1, 2016.
11. 11 Meyer, A.M., Olshan, A., Green, L., et al. Big data for population-based cancer research: the integrated cancer information and surveillance system. N C Med J 75 (2014), 265–268.
12. 12 Lund, J.L., Sturmer, T., Harlan, L.C., et al. Identifying specific chemotherapeutic agents in Medicare data: a validation study. Med Care 51 (2013), e27–e34.
13. 13 Uterine cancer North Carolina central cancer registry fact sheets. North Carolina, State Center for Health Statistics, 2011. Available at: http://www.schs.state.nc.us/schs/pdf/Uterine_Cancer_2011.pdf. Accessed February 23, 2016.
14. 14 Young, J.L. Jr., Roffers, S.D., Ries, L.A.G., et al. (eds.) SEER summary staging manual–2000: codes and coding instructions, 2001, National Cancer Institute, Bethesda (MD).
15. 15 Parker, T., Rural-urban continuum codes. 2013, US Department of Agriculture Economic Research Service, Washington (DC).
16. 16 Gagne, J.J., Glynn, R.J., Avorn, J., et al. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol 64 (2011), 749–759.
17. 17 Gehrig, P.A., Morris, D.E., Van Le, L., Uterine serous carcinoma: a comparison of therapy for advanced-stage disease. Int J Gynecol Cancer 14 (2004), 515–520.
18. 18 Dietrich, C.S. III, Modesitt, S.C., DePriest, P.D., et al. The efficacy of adjuvant platinum-based chemotherapy in stage I uterine papillary serous carcinoma (UPSC). Gynecol Oncol 99 (2005), 557–563.
19. 19 Alvarez Secord, A., Havrilesky, L.J., Bae-Jump, V., et al. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer. Gynecol Oncol 107 (2007), 285–291.
20. 20 Havrilesky, L.J., Secord, A.A., Bae-Jump, V., et al. Outcomes in surgical stage I uterine papillary serous carcinoma. Gynecol Oncol 105 (2007), 677–682.
21. 21 Fader, A.N., Drake, R.D., O'Malley, D.M., et al. Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer 115 (2009), 2119–2127.
22. 22 Fader, A.N., Nagel, C., Axtell, A.E., et al. Stage II uterine papillary serous carcinoma: carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes. Gynecol Oncol 112 (2009), 558–562.
23. 23 Bristow, R.E., Chang, J., Ziogas, A., et al. Adherence to treatment guidelines for ovarian cancer as a measure of quality care. Obstet Gynecol 121 (2013), 1226–1234.
24. 24 Murphy, C.C., Harlan, L.C., Lund, J.L., et al. Patterns of colorectal cancer care in the United States: 1990-2010. J Natl Cancer Inst, 107(10), 2015.
25. 25 Bristow, R.E., Chang, J., Ziogas, A., et al. Spatial analysis of adherence to treatment guidelines for advanced-stage ovarian cancer and the impact of race and socioeconomic status. Gynecol Oncol 134 (2014), 60–67.
26. 26 Baldwin, L.M., Cai, Y., Larson, E.H., et al. Access to cancer services for rural colorectal cancer patients. J Rural Health 24 (2008), 390–399.
27. 27 Wheeler, S.B., Kuo, T.M., Durham, D., et al. Effects of distance to care and rural or urban residence on receipt of radiation therapy among North Carolina Medicare enrollees with breast cancer. N C Med J 75 (2014), 239–246.
28. 28 Shalowitz, D.I., Vinograd, A.M., Giuntoli, R.L. II, Geographic access to gynecologic cancer care in the United States. Gynecol Oncol 138 (2015), 115–120.
29. 29 Hershman, D.L., Wright, J.D., Comparative effectiveness research in oncology methodology: observational data. J Clin Oncol 30 (2012), 4215–4222.
30. 30 Dickson, V., The challenge of churning. Insurers and states seek to ensure coverage continuity between Medicaid and private plans. Mod Healthc 44 (2014), 21–23.
31. 31 Matsuo, K., Opper, N.R., Ciccone, M.A., et al. Time interval between endometrial biopsy and surgical staging for type I endometrial cancer: association between tumor characteristics and survival outcome. Obstet Gynecol 125 (2015), 424–433.
32. 32 Cohen, R., Martinez, M., Health insurance coverage: early release of estimates from the National Health Interview Survey, 2014. 2015, National Center for Health Statistics, Atlanta (GA).